Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

BR96-doxorubicin immunoconjugate

An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin. The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types. Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BR96-DOX immunoconjugate
BR96-doxorubicin
BR96-doxorubicin conjugate
cBR96-doxorubicin immunoconjugate
Abbreviation:BR96-DOX
Code name:BMS-182248-01
SGN-15
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search